ASCO’s 2021 Advance of the Year highlights how progress in the treatment of gastrointestinal (GI) cancers is driven by molecular testing of tumors.
Dr. Neeraj Agarwal discusses 3 clinical trials presented at the 2020 ESMO Virtual Congress that studied new treatments for advanced kidney cancer, prostate cancer, and bladder cancer.
In this podcast, Cancer.Net Associate Editors share exciting research from the ASCO20 Virtual Scientific Program.
ASCO20 Virtual Scientific Program: Immunotherapy for Colorectal Cancer, Maintenance Therapy for Bladder Cancer, Precision Medicine in Childhood Cancers, Treatment for Gestational Trophoblastic Disease, and Targeted Therapy for Non-Small Cell Lung Cancer
Read research highlights just released from the ASCO20 Virtual Scientific Program. They include studies on immunotherapy for metastatic colorectal cancer and gestational trophoblastic disease, maintenance therapy for advanced bladder cancer, the potential of precision medicine for childhood cancers, and targeted therapy after surgery for EGFR-positive non-small cell lung cancer.
Programa científico virtual de ASCO20: Inmunoterapia para el cáncer colorrectal metastásico, terapia de mantenimiento para el cáncer de vejiga, medicina de precisión para el cáncer infantil, inmunoterapia para la ETG y terapia dirigida para el NSCLC
Lea los puntos destacados de la investigación del programa científico virtual ASCO20 que se acaban de publicar. Incluyen estudios sobre inmunoterapia para el cáncer colorrectal metastásico y la enfermedad trofoblástica gestacional, terapia de mantenimiento para el cáncer de vejiga avanzado, el potencial de la medicina de precisión para el cáncer infantil y la terapia dirigida después de la cirugía por EGFR (receptor del factor de crecimiento epidérmico), positivo de cáncer de pulmón de células no pequeñas.
Dr. Ricardo Cubedo describes 3 research highlights from the ESMO 2019 Congress, including targeted therapy for ovarian cancer, immunotherapy for lung cancer, and more study data on targeted tumor-agnostic treatment.
Learn how tumor marker tests can help doctors diagnose cancer and plan the best possible treatment plan for each person.
ASCO Annual Meeting 2019: Laparoscopic Surgery for Metastatic Colorectal Cancer, Expanding Eligibility Criteria for Advanced Non-Small Cell Lung Cancer, and a New Targeted Therapy for Advanced Bladder Cancer
The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include minimally invasive surgery for liver metastases in colorectal cancer, expanding clinical trial eligibility criteria for non-small cell lung cancer, and a new targeted therapy for advanced bladder cancer.
ASCO Annual Meeting 2019: Treatment Advances for Metastatic Prostate Cancer and Pancreatic Cancer, Multiple Myeloma Survival Factors, and Effects of the Affordable Care Act on Cancer Care
The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include an effective medication for metastatic prostate cancer, targeted therapy that slows the growth of metastatic pancreatic cancer, how socioeconomic factors may affect survival for multiple myeloma, and how the ACA resulted in earlier treatment and improved equality in care.
ASCO Annual Meeting 2019: Immunotherapy for Lung Cancer, Gastrointestinal Cancers and Targeted Therapy for Breast Cancer
The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include treatment advances for advanced lung cancer, stomach cancer, gastroesophageal junction cancer, and breast cancer.